European regulators validate Cempra's drug application
European regulators have validated an application by Chapel Hill drug developer Cempra (Nasdaq: CEMP), a move that formally starts the review process.
Cempra has developed a new pneumonia treatment that is not susceptible to antibiotic resistance. These superbugs present a threat to modern medicine because antibiotics are used for many treatments.
Cempra's treatment, called solithromycin, has shown it is not susceptible to antibiotic resistance.
The European Medicines Agency, Europe's version...